ADARx Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ADRX | GPCR | ARWR | 2257.HK | PRTA | ALEC | |
|---|---|---|---|---|---|---|
| Market cap | 1.66B | 1.45B | 8.71B | 463.71M | 430.72M | 254.58M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -9.9 | -9.6 | -12.4 | — | -6.4 | -3.1 |
| Price/book | -0.7 | 1.1 | 18.7 | -9.5 | 1.5 | -25.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −22.69% | −36.82% | +47.68% | −51.51% | −20.06% | +63.35% |
| Today | −7.02% | +0.05% | +3.56% | −0.12% | +2.19% | +11.22% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ADRX news ›ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Stock Has Average Target Price of $35.00
Posted by Defense World Staff on Oct 26th, 2026 Read Our Latest Report on ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins…
ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded at Zacks Research
Zacks Research upgraded shares of ADARx Pharmaceuticals (NASDAQ:ADRX – Free Report) to a hold rating in a research note published on Wednesday morning,Zacks reports. ADRX has been the topic of several other reports. Wall Street Zen raised…
ADARx Pharmaceuticals, Inc. (ADRX) – What Are Analysts Thinking About This Stock?
Shares of ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has…
ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded to Strong-Buy at UBS Group
ADARx Pharmaceuticals (NASDAQ:ADRX - Get Free Report) was upgraded by UBS Group to a "strong-buy" rating in a report released on Tuesday, Zacks reports. View Our Latest Analysis on ADARx Pharmaceuticals Shares of ADRX stock opened at…
Recent Investment Analysts’ Ratings Updates for ADARx Pharmaceuticals (ADRX)
Posted by Mitch Edgeman on Oct 21st, 2026 ADARx Pharmaceuticals (NASDAQ: ADRX) recently received a number of ratings updates from brokerages and research firms: ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company…
ADARx Pharmaceuticals (NASDAQ:ADRX) Stock Picked Up by Analysts at JPMorgan Chase & Co.
Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of ADARx Pharmaceuticals (NASDAQ:ADRX - Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set an "overweight"…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net2
- marketbeat.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.